Lung NeoplasmNCT06505642
nCLE-Cone-beam CT Navigation Bronchoscopy
A study testing needle-based confocal laser endomicroscopy in people with Lung Neoplasm and Peripheral Lung Parenchyma Tumor, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.
Trial summary
The goal of this proof of principle observational study is to investigate in patients with suspected peripheral pulmonary nodules. The main question it aims to answer is: What is the concordance between CBCT navigation success (tool-in-lesion on CBCT spin) and nCLE tool-in-lesion confirmation (tool-in-lesion nCLE… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Neoplasm, Peripheral Lung Parenchyma Tumor, Lung Cancer
- What is being tested?
- needle-based confocal laser endomicroscopy
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- 1 siteNetherlands
- Study dates
- 8 Oct 2024to Jun 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 18 years or older
- Suspected pulmonary nodule with an indication for CBCT-NB (decided by multidisciplinary tumour board)
- Nodule must be solid or partially solid
- Solid part of the nodule must be at least 8 mm
- Largest dimension of the nodule on CT equal or less than 30 mm
- Ability to understand and willingness to sign a written informed consent
Who cannot join
- Inability or non-willingness to provide informed consent
- Patients with an endobronchial visible lung tumor on bronchoscopic inspection
- Patients in which the target lesion is within reach of the linear EBUS scope
- Lung nodules that resolved at the time of index intraprocedural CBCT
- Failure to comply with the study protocol
- Patients with known allergy for fluorescein or risk factors for an allergic reaction
Show all 12Show fewer
- Pregnant or breastfeeding women
- Patients with hemodynamic instability
- Patients with refractory hypoxemia
- Patients with a therapeutic anticoagulant that cannot be held for an appropriate in-terval before the procedure
- Patients who are unable to tolerate general anesthesia according to the anesthesiologist
- Patient undergoing chemotherapy as several chemotherapies have fluorescent properties at the same wavelength (e.g. doxorubicin)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Combined Needle-based Confocal Laser Endomicroscopy Cone-Beam Computed Tomography Navigation Bronchoscopy: a Proof of Principle Study
The goal of this proof of principle observational study is to investigate in patients with suspected peripheral pulmonary nodules. The main question it aims to answer is:
- What is the concordance between CBCT navigation success (tool-in-lesion on CBCT spin) and nCLE tool-in-lesion confirmation (tool-in-lesion nCLE criteria observed).
Read more
Participants scheduled to undergo a diagnostic conebeam navigation bronchoscopy will be included in the study. nCLE imaging at the tip of the TBNA needle will be added to the procedure for study purposes.
Two needle punctures of the pulmonary nodule will be followed by nCLE imaging directly followed by a tool-in-lesion CBCT spin in order to compare nCLE results with CBCT results.
Read the detailed description
Lung cancer remains a significant problem in current society with one of the higher cancer related mortality rates. The increased use of chest computed tomography (CT) and the po-tential future lung cancer screening result in an increased detection of early-stage peripheral lung cancer. Bronchoscopies are often indicated to collect tissue for diagnosis and to aid treatment decision making.
Diagnostic bronchoscopy for peripheral lung nodules remains challenging despite many tech-nological innovations. The procedure comprises three essential pillars needed for a diagnos-tic success: navigation to the lesion, tool-in-lesion confirmation and adequate tissue retrieval.
Cone beam computed tomography navigation bronchoscopy (CBCT-NB) is a fairly new tech-nique that provides coarse navigation to the pulmonary lesion with real-time guidance using augmented fluoroscopy (AF). An initial CBCT scan allows for segmentation of the target le-sion and selecting the optimal pathway. Repeated CBCT scanning allows for confirmation that the target has been reached (navigation success) or if repositioning is needed.
Although the technique is very promising, an often discussed disadvantage of CBCT is the inherent use of ionizing radiation, limited availability and challenges with small nodules lo-cated in the basal and posterior fields due to respiratory motion. Most procedures ask for multiple CBCT spins both for trajectory planning, tool adjustments and tool-in-lesion confir-mation. This, combined with extensive use of fluoroscopy is associated with radiation expo-sure for both patients and the investigation team. Additionally, CBCT-NB with AF provides information from a global perspective rather than a local perspective. In experienced centers, coarse navigation guidance seems of lesser concern and fine positioning and optimal tissue sampling are the biggest problems to be overcome. The persistently low diagnostic yield of navigation bronchoscopies can for the majority be attributed mispositioning of the tools in "the last centimeter". Therefore there is a need for complementary techniques providing real-time information for fine-tuning the needle position such as needle-based confocal laser en-domicroscopy (nCLE) also called the "smart needle".
Confocal laser endomicroscopy (CLE) is a high-resolution microscopic technique that visual-izes individual cells in real-time at the tip of the biopsy needle, allowing for real-time micro-scopic feedback for fine tuning needle positioning and tool-in-lesion confirmation. Currently, it is unknown which (combination of) techniques are the most optimal (i.e., leading to a high di-agnostic yield and cost-effective). Therefore, research is needed to investigate the potential of new (combinations of) techniques. To date, there are no reports on the combination of CBCT-NB with nCLE.
Objective: This study aims to investigate proof of principle of utilizing nCLE during CBCT-NB navigation bronchoscopy. A confirmatory CBCT spin is considered the gold standard for tool-in-lesion but is associated with additional radiation exposure. The aim is to investigate the concordance between CBCT navigation success (tool-in-lesion on CBCT spin) and nCLE tool-in-lesion confirmation (tool-in-lesion nCLE criteria observed). The investigators also hypothesize that nCLE could reduce or replace the need for additional confirmatory CBCT scans and limit fluoroscopy use.
Study design: Investigator-initiated proof of principle medical device study
Study population: Patients (18 years and older) with (suspected) pulmonary nodules with an indication for cone-beam computed tomography navigation bronchoscopy.
Procedure: Cone beam computed tomography navigation bronchoscopy combined with needle-based confocal laser endomicroscopy.
Main study parameters/endpoints:
- CBCT-NB navigation success as either tool-in-lesion OR unsuccessful
- nCLE tool-in-lesion confirmation, defined as tool-in-lesion nCLE criteria observed
- Conditions
- Lung Neoplasm, Peripheral Lung Parenchyma Tumor, Lung Cancer
- Being tested
- needle-based confocal laser endomicroscopy
- Keywords
- Confocal Laser Endomicroscopy, Bronchoscopy, Cone beam computed tomography, Image guided bronchoscopy
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
needle-based confocal laser endomicroscopyDevice
Also called cone beam computed tomography navigation bronchoscopy
needle-based confocal laser endomicroscopy at the tip of the TBNA needle for two punctures, combined with confirmatory CBCT spin for tool-in-lesion confirmation
| Study group | Role | What they receive |
|---|---|---|
| nCLE + CBCT-NB | Experimental | Patients with a suspected malignant peripheral pulmonary nodule(s) referred for cone beam ct navigation bronchoscopy for tissue sampling. Receives: Device: needle-based confocal laser endomicroscopy |
What is being measured
The primary outcome is the main question the study is designed to answer.
CBCT navigation success and nCLE tool-in-lesion confirmation
CBCT-NB navigation success: tool-in-lesion OR unsuccessful navigation nCLE tool-in-lesion confirmation: in-lesion nCLE criteria seen
Measured: Intra-procedure
Secondary outcomes (7)
Technical feasibility
Proportion of nCLE imaging that are successful (meaning that the preloaded needle can be advanced through the working channel, puncture the nodule, advance the CLE probe and start imaging) resulting good quality images.
Measured: Intra-procedure
Safety
Number and proportion of (severe) adverse events ((S)AEs) and investigational procedure related adverse events (AEs)
Measured: Up to 7 days post procedure
Diagnostic yield
Proportion (expressed in percentages) of patients in whom the bronchoscopic procedure results in a definitive diagnosis out of the total number of patients that have received the diagnostic bronchoscopic procedure.
Measured: up to 6 months post procedure
Diagnostic sensitivity for malignancy
Proportion (expressed in percentages) of patients that have malignancy diagnosed by bronchoscopic tissue sampling, relative to the total number of patients with a final diagnosis of malignancy as determined by the reference standard.
Measured: up to 6 months post procedure
Sensitivity, specificity and accuracy of real-time nCLE imaging assessment
Sensitivity, specificity and accuracy of real-time nCLE imaging assessment all described in percentages.
Measured: Intra-procedure
Sensitivity, specificity and accuracy of post-procedure nCLE image assessment
Sensitivity, specificity and accuracy of post-procedure nCLE image assessment described as percentages.
Measured: Intra-procedure
Interobserver agreement (IOA) and intraobserver reliability (IOR)
Interobserver agreement (IOA) represented by the Cohen's kappa statistics (mean with 95% confidence intervall) and intraobserver reliability (IOR) represented by the Cohen's kappa statistics (mean +/- standard deviation)
Measured: Intra-procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2024
- Study start8 Oct 2024
- Primary completion16 Dec 2025
- Study completionJun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung NeoplasmStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 25 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Prof. J.T. Annema, MD, PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Investigators
- Jouke Annema, MD, PhD, Principal investigator, Amsterdam UMC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06505642
- Sponsor's protocol ID
- NL86502.018.24
- Status last verified
- Apr 2026
- First submitted
- 11 Jul 2024
- Last updated
- 7 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 7 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Combined Needle-based Confocal Laser Endomicroscopy Cone-Beam Computed Tomography Navigation Bronchoscopy: a Proof of Principle Study
- ClinicalTrials.gov ID
- NCT06505642
- Acronym / sponsor ID
- NL86502.018.24
- Conditions
- Lung Neoplasm, Peripheral Lung Parenchyma Tumor, Lung Cancer
- Keywords
- Confocal Laser Endomicroscopy, Bronchoscopy, Cone beam computed tomography, Image guided bronchoscopy
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 25 participants (estimated)
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)University, hospital or other
- Study start
- 8 Oct 2024 (actual)
- Primary completion
- 16 Dec 2025 (actual)
- Study completion
- Jun 2026 (estimated)
- First posted
- 17 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this proof of principle observational study is to investigate in patients with suspected peripheral pulmonary nodules. The main question it aims to answer is:
- What is the concordance between CBCT navigation success (tool-in-lesion on CBCT spin) and nCLE tool-in-lesion confirmation (tool-in-lesion nCLE criteria observed).
Participants scheduled to undergo a diagnostic conebeam navigation bronchoscopy will be included in the study. nCLE imaging at the tip of the TBNA needle will be added to the procedure for study purposes.
Two needle punctures of the pulmonary nodule will be followed by nCLE imaging directly followed by a tool-in-lesion CBCT spin in order to compare nCLE results with CBCT results.
Detailed description
Lung cancer remains a significant problem in current society with one of the higher cancer related mortality rates. The increased use of chest computed tomography (CT) and the po-tential future lung cancer screening result in an increased detection of early-stage peripheral lung cancer. Bronchoscopies are often indicated to collect tissue for diagnosis and to aid treatment decision making.
Diagnostic bronchoscopy for peripheral lung nodules remains challenging despite many tech-nological innovations. The procedure comprises three essential pillars needed for a diagnos-tic success: navigation to the lesion, tool-in-lesion confirmation and adequate tissue retrieval.
Cone beam computed tomography navigation bronchoscopy (CBCT-NB) is a fairly new tech-nique that provides coarse navigation to the pulmonary lesion with real-time guidance using augmented fluoroscopy (AF). An initial CBCT scan allows for segmentation of the target le-sion and selecting the optimal pathway. Repeated CBCT scanning allows for confirmation that the target has been reached (navigation success) or if repositioning is needed.
Although the technique is very promising, an often discussed disadvantage of CBCT is the inherent use of ionizing radiation, limited availability and challenges with small nodules lo-cated in the basal and posterior fields due to respiratory motion. Most procedures ask for multiple CBCT spins both for trajectory planning, tool adjustments and tool-in-lesion confir-mation. This, combined with extensive use of fluoroscopy is associated with radiation expo-sure for both patients and the investigation team. Additionally, CBCT-NB with AF provides information from a global perspective rather than a local perspective. In experienced centers, coarse navigation guidance seems of lesser concern and fine positioning and optimal tissue sampling are the biggest problems to be overcome. The persistently low diagnostic yield of navigation bronchoscopies can for the majority be attributed mispositioning of the tools in "the last centimeter". Therefore there is a need for complementary techniques providing real-time information for fine-tuning the needle position such as needle-based confocal laser en-domicroscopy (nCLE) also called the "smart needle".
Confocal laser endomicroscopy (CLE) is a high-resolution microscopic technique that visual-izes individual cells in real-time at the tip of the biopsy needle, allowing for real-time micro-scopic feedback for fine tuning needle positioning and tool-in-lesion confirmation. Currently, it is unknown which (combination of) techniques are the most optimal (i.e., leading to a high di-agnostic yield and cost-effective). Therefore, research is needed to investigate the potential of new (combinations of) techniques. To date, there are no reports on the combination of CBCT-NB with nCLE.
Objective: This study aims to investigate proof of principle of utilizing nCLE during CBCT-NB navigation bronchoscopy. A confirmatory CBCT spin is considered the gold standard for tool-in-lesion but is associated with additional radiation exposure. The aim is to investigate the concordance between CBCT navigation success (tool-in-lesion on CBCT spin) and nCLE tool-in-lesion confirmation (tool-in-lesion nCLE criteria observed). The investigators also hypothesize that nCLE could reduce or replace the need for additional confirmatory CBCT scans and limit fluoroscopy use.
Study design: Investigator-initiated proof of principle medical device study
Study population: Patients (18 years and older) with (suspected) pulmonary nodules with an indication for cone-beam computed tomography navigation bronchoscopy.
Procedure: Cone beam computed tomography navigation bronchoscopy combined with needle-based confocal laser endomicroscopy.
Main study parameters/endpoints:
- CBCT-NB navigation success as either tool-in-lesion OR unsuccessful
- nCLE tool-in-lesion confirmation, defined as tool-in-lesion nCLE criteria observed
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| nCLE + CBCT-NB | Experimental | Device: needle-based confocal laser endomicroscopyPatients with a suspected malignant peripheral pulmonary nodule(s) referred for cone beam ct navigation bronchoscopy for tissue sampling. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- 18 years or older
- Suspected pulmonary nodule with an indication for CBCT-NB (decided by multidisciplinary tumour board)
- Nodule must be solid or partially solid
- Solid part of the nodule must be at least 8 mm
- Largest dimension of the nodule on CT equal or less than 30 mm
Key exclusion criteria (12 listed)
- Inability or non-willingness to provide informed consent
- Patients with an endobronchial visible lung tumor on bronchoscopic inspection
- Patients in which the target lesion is within reach of the linear EBUS scope
- Lung nodules that resolved at the time of index intraprocedural CBCT
- Failure to comply with the study protocol
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| needle-based confocal laser endomicroscopyAlso: cone beam computed tomography navigation bronchoscopyneedle-based confocal laser endomicroscopy at the tip of the TBNA needle for two punctures, combined with confirmatory CBCT spin for tool-in-lesion confirmation | Device | nCLE + CBCT-NB |
Primary outcome
CBCT navigation success and nCLE tool-in-lesion confirmation
Time frame: Intra-procedure
CBCT-NB navigation success: tool-in-lesion OR unsuccessful navigation nCLE tool-in-lesion confirmation: in-lesion nCLE criteria seen
7 secondary outcomes
Technical feasibility
Time frame: Intra-procedure
Safety
Time frame: Up to 7 days post procedure
Diagnostic yield
Time frame: up to 6 months post procedure
Diagnostic sensitivity for malignancy
Time frame: up to 6 months post procedure
Sensitivity, specificity and accuracy of real-time nCLE imaging assessment
Time frame: Intra-procedure
Sensitivity, specificity and accuracy of post-procedure nCLE image assessment
Time frame: Intra-procedure
Interobserver agreement (IOA) and intraobserver reliability (IOR)
Time frame: Intra-procedure
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Apr 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Lung Neoplasm
Recruiting
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
Lung Neoplasms, Neoadjuvant Therapy
Not yet recruitingPhase 3
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (Icc)
Active, not recruitingPhase 3
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
Non-small Cell Lung Cancer Stage IV
RecruitingObservational study
Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.
Lung Cancer
RecruitingPhase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jouke Annema, MD, PhD principal investigator
Amsterdam UMC
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing needle-based confocal laser endomicroscopy in people with Lung Neoplasm and Peripheral Lung Parenchyma Tumor, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 7 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
CBCT navigation success and nCLE tool-in-lesion confirmation (time frame: Intra-procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2026.